CA-TEMENOS
29.1.2020 10:07:03 CET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, and Google Cloud today announced a global, strategic partnership to help financial services organizations run mission-critical banking software and applications on Google Cloud, create profitable business models, and improve and differentiate their customer experiences.
The two companies began collaborating in 2019 to integrate Temenos cloud-native, cloud-agnostic software into Google Cloud and have demonstrated success with joint banking customers in Europe and Asia. Under this expanded partnership, Temenos’ full suite of banking software and applications will now be available on Google Cloud, and the two companies will help banks go to market faster, open up new business models, and achieve tangible business benefits.
More than 3,000 financial services institutions around the world leverage Temenos’ modern, cloud-native and API-first technology. As a part of this strategic partnership, banks can run Temenos’ applications in Google Cloud, taking advantage of its scalability, resilience, and global infrastructure. The expanded partnership was announced today at the Paris Fintech Forum 2020, where Max Chuard, Temenos CEO, spoke about ‘Banking in the Cloud’.
In addition, building upon its open approach to cloud, Temenos will be the first global banking software provider to run on Google Cloud’s Anthos, enabling customers to deliver mission-critical workloads across on-premises and cloud environments, or even across multiple clouds.
Anthos is Google Cloud’s hybrid and multi-cloud application platform that enables organizations to migrate and modernize their existing applications, build new ones and run them anywhere, whether it’s in the cloud, on-premises or on multiple clouds. Built on open-source technology pioneered by Google, such as Kubernetes, Istio and containers, it helps banks empower their developers, security professionals, platform teams and operations engineers — enhancing employee and customer experiences, saving bottom-line costs and increasing top-line revenue.
Max Chuard, Chief Executive Officer, Temenos, said: “We see an explosive growth in cloud adoption in the banking industry. We are delighted to extend our leadership in the cloud and strengthen our strategic partnership with Google Cloud, a leader in innovation in cloud computing. As a strategic global banking software partner of Google Cloud, we will bring to market innovative solutions that combine our API-first, cloud-native, microservices-based banking software with Google Cloud’s scale and leading cloud capabilities. Our customers will benefit from the winning combination of Temenos’ functionally rich and technologically advanced digital banking platform on Google Cloud. Together, we will enable banks to reduce their time to market and operational complexity, as well as elastically scale and deliver outstanding digital customer experiences. With Google Cloud’s Anthos, we give banks the freedom to innovate and reap the true benefits of multi-cloud.”
Thomas Kurian, Chief Executive Officer, Google Cloud, said: “Temenos delivers market-leading banking software applications to thousands of the world’s leading financial services organizations, and we’re excited to expand our strategic alliance with them. Extending Temenos’ core capabilities to Google Cloud helps banks digitally transform their business and deliver entirely new customer experiences and offerings.”
Temenos has been in the forefront of software innovation, consistently investing 20% of its revenues in R&D and is pioneering in cloud banking for the last 10 years. Temenos enables banks to significantly reduce their total cost of ownership through elastic cloud scalability, distributed database technology and multi-cloud resilience, all underpinned by the benefits of vendor and platform independence. Temenos accelerates banks digital transformation helping them to become more agile and innovate faster.
– Ends –
About Google Cloud
Google Cloud provides organizations with leading infrastructure, platform capabilities and industry solutions, along with expertise, to reinvent their business with data-powered innovation on modern computing infrastructure. We deliver enterprise-grade cloud solutions that leverage Google’s cutting-edge technology to help companies operate more efficiently, modernize for growth and innovate for the future. Customers in more than 150 countries turn to Google Cloud as their trusted partner to solve their most critical business problems.
About Temenos
Temenos AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic front office and core banking, payments, fund management and wealth management software products enabling banks to deliver consistent, frictionless customer journeys and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve industry-leading cost-income ratios of 26.8% and returns on equity of 25.0%, 2X better than the industry average. These clients also invest over 53% of their IT budget on growth and innovation versus maintenance, which is 2.5X the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005293/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom